Page 1 of 24 
YALE UNIVERSITY 
 HUMAN INVESTIGATION COMMITTEE  
Application to Involve Human Subjects in Biomedical Research  
100 FR1 (2013-1) 
 
 
SECTIO N I: ADMINISTRATIVE INFORMATION  
Title of Research Project:  
Prostate Cancer Screening in Men with Germline BRC A2 mutation s 
Principal Investigator:  
Preston C. Sprenkle  Yale Academic Appointment:  
Assistant Professor  
Department:  Urology  
Campus Address:   
Department of Uro logy, Fi tkin Memorial Pavilion Suite 315b , PO Box 208058  
Campus Phone:  
203-785-2815  Fax:  
203-785-4043 Pager:  
475-201-5778 E-mail:   
preston.sprenkle@yale.edu  
Protocol Correspondent Name & Address  (if different than PI ): 
 Cayce Nawaf  
Campus Phone:  203-785-2815  Fax:  203-
785-4043 E-mail:  cayce.nawaf@yale.edu  
Yale Cancer Center CTO Protocol Correspondent Name & Address ( if applicable ): 
Campus Phone:  Fax:  E-mail:  
Business Manager: 
Campus Phone  : Fax : E-mail : 
Invest
igator Interests : Faculty Advisor :(required if PI is a student, 
resident , fellow  or other trainee )            NA  Yale Academic Appointment:  
Campus Address:  
Campus Phone:  Fax:  Pager:  E-mail:  DATE STAMPED -RECEIVED  PROTOCOL NUMBER  Please refer to the HIC website for application 
instructions a nd information required to complete 
this application.  The Instructions are available at 
http://www.yale.edu/hrpp/forms -
templates/biomedical.html   
Submit the original application and one (1) copy  
of all materials including relevant sections of the 
grant which funds this  project (if applicable) to 
the HIC.   HIC  OFFICE USE ONLY Final Protocol  3/29/2019

Page 2 of 24 
 Does the principal investigator, or do any research personnel who are responsible for the design, 
conduct or reporting of this project or any of their family member s (spouse or dependent child) 
have an incentive or interest , financial o r otherwise,  that may  affect the protection of the human 
subjects involved in this project, the scientific objectivity of the research or it s integrity?  Note:  
The Principal Investigator (Project Director), upon consideration of the individual‚Äôs role and degree of independence in carrying out the work, will determine who is responsible for t he 
design, conduct, or reporting of the research.  
See Disclosures and Management of Personal Interests in Human Research http://www.yale.edu/hrpp/policies/index.html#COI
  
ÔÅØ  Yes   ‚ñ†  No   
 Do you or does anyone on the research team who is determined by you to be responsible for the design, conduct or reporting of this research have any patent (sol e right to make, use or sell an  
invention) or copyright (exclusive rights to an original work) interests related to this research protocol? 
ÔÅØ  Yes   ‚ñ†  No   
   
If yes  to either question above, l ist names  of the investigator or responsible person: 
   The Yale University Principal Investigator, all Yale University co -investigators, and all Yale 
University individuals who are responsible for the design, conduct or reporting of research must have a current financial disclosure form on file with the University‚Äôs Conflict of Interest Office. Yale New Haven Hospital personnel who are listed as con- investigators on a protocol with a 
Yale University Principal Investigator must also have a current financial disclosure form on file with the University‚Äôs Conflict of Interest Office. If this has not been done, the individual(s) 
should follow this link to the COI Office Website to complete the form:  http://www.yale.edu/coi/
   
 NOTE: The requirement for maintaining a current disclosure form on file with the University‚Äôs Conflict of Interest Office extends primarily  to Yale University and Yale- New Haven Hospital 
personnel.  Whether or not they are required to maintain a disclosure form with the 
University‚Äôs Conflict of Interest Office, all investigators and individuals deemed otherwise 
respons ible by the PI who are  listed on the protocol are required to disclose to the PI any 
interests that are specific to this protocol.  
 
SECTION II: GENERAL INFORMATION  
 
1. Performing Organizations:  Identify the hospital, in -patient or outpatient facility, school or 
other agency that will serve as the location of the research.  Choose all that apply: 
  
a. Internal Location[s] of the Study: 
 Magnetic Resonance Research Center     Yale University PET Center  
     (MR -TAC)         YCCI/Church Street Research Unit (CSRU)  
 Yale Cancer Center /Clinical Trials Office (CTO)      YCCI/Hospital Research Unit (HRU) 

Page 3 of 24 
  Yale Cancer Center /Smilow     YCCI/Keck Laborato ries 
 Yale -New Haven Hospital      Yale -New Haven Hospital ‚ÄîSaint Raphael Campus 
 Cancer Data Repository/Tumor Registry  
 Specify Other Yale Location:    
 
 
b. External Location[s]: 
 APT Foundation, Inc.     Haskins Laboratories  
 Connecticut Mental Health Center    John B. Pierce Laboratory, Inc. 
 Clinical Neuroscience Research Unit (C NRU) Veterans Affairs Hospital, West Haven   
 Other Locations, Specify:     International Research Site   
(Specify location(s)):  
 
 
c. Additional Required Documents (check all that apply) :  N/A 
*YCCI -Scientific and Safety Committee (YCCI -SSC)   Approval Date:  
*Pediatric Protocol Review Committee (PPRC)    Approval Date:  
*YCC Protocol Review Committee (YRC -PRC)   Approval Date:  
*Dept. of Veterans Affairs , West Haven VA HSS   Approval Date:  
*Radioactive Drug Research Committee (RDRC)   Approval Date:  
 YNHH- Radiation Safety Committee (YNHH -RSC)   Approval Date:  
 Magnetic Resonance Research Center PRC (MRRC -PRC)  Approval Date:  
 YSM/YNHH Cancer Data Repository (CaDR)    Approval Date:  
 Dept. of Lab Medicine request for services or specimens form 
 Imaging on YNHH Diagnostic Radiology equipment request form (YDRCTO request) found at 
 http://radiology.yale.edu/research/ClinTrials.aspx ) 
*Approval from these committees is required before final HIC approval is granted. See instructions for documents required for initial submission and approval of the protocol. Allow sufficient time for these requests. Check with the oversight body for their time requirements.  
 
2. Probable Duration of Project: State the expected duration of the project, including all follow-up and data analysis activities.  
 
Ongoing 
 
3. Research Type/Phase: (Check all that apply)  
a. Study Type  
    Single Center Study  
    Multi- Center Study  
Does the Yale PI serve as the PI of the multi -site study? Yes  No  
   Coordinating Center/Data Management 
   Other:  
 
 
b. Study Phase   N/A 
     Pilot    Phase I   Phase II   Phase III   Phase IV  
     Other ( Specify)   

Page 4 of 24 
  
 
4. Area of Research: (Check all that apply) Note that these are overlapping definitions and 
more than one category may apply to your research protocol. Definitions for the following 
can be found  in the instructions section 4c: 
 Clinical Research: Patient -Oriented       Clinical Research: Outcomes and  
 Clinical Research: Epidemiologic and Behavioral                   Health Services  
 Translational Research #1 (‚ÄúBench -to-Bedside‚Äù)        Interdisciplinary Research  
 Translational Research #2 (‚ÄúBedside- to-Community‚Äù)   Community- Based Research  
 
 
5.   Is this study a clinical trial? Yes  No  
NOTE the current ICMJE  (International Committee of Medical Journal Editors) definition of a 
clinical trial: ‚Äú any research study that prospectively assigns human participants or groups of humans 
to one or more health-related interventions to evaluate the effects on health outcomes.‚Äù Health- related 
interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process -of-care changes). Health outcomes include any biomedical or health- related measures 
obtained in patients or participants, including pharmacokinetic measures and adverse events‚Äù  
  If yes, where is it registered?  
   Clinical Trials.gov registry  
   Other ( Specify )  
 
Registration of clinical trials at their initiation  is required by the FDA, NIH and by the ICMJE. 
 
If this study is registered on clinicaltrials.gov, there is new language in the consent form and compound 
authorization that should be used. 
For more information on registering clinical trials, including whether your trial must be 
registered, see the YCCI webpage, http://yc ci.yale.edu/researchers/ors/registerstudy.aspx  or 
 contact YCCI at 203.785.3482) 
 
6. Does the Clinical Trials Agreement (CTA) require compliance with ICH GCP (E6)?  
Yes   No  
 
 
7. Will this study have a billable service ? A Billable Service is defined  as a service or procedure 
that will be ordered, performed or result in charging  in EPIC for individuals who are enrolled in 
a clinical research study, regardless  if the charge is intended to be paid by the subject/their 
insurance or the research study.  
 
Yes   No  
If you answered "yes", this study will need to be set up in OnCore Support  
http://medicine.yale.edu/ymg/systems/ppm/index. aspx  
 

Page 5 of 24 
 8. Are there any procedures involved in this protocol that will be performed at YNHH or one of 
its affiliated entities?   Yes XX No  ___  If Yes, please answer questions a through c and note 
instructions below.  If No, proceed to Section III.  
a. Does  your YNHH privilege delineation currently include the specific procedure that you will 
perform?  - Yes  
b. Will you be using any new equipment or equipment that you have not used in the past for 
this procedure? - No  
  c. Will a novel approach using existing equipment be applied? - No  
  If you answered ‚Äúno‚Äù to question 7a, or "yes" to question 7b or c, please contact the YNHH 
Department of Physician Services (688 -2615) for prior approval before commencing with your 
research protocol
. 
 
SECTION III: FUNDING , RESEARCH TEAM AND TRAINING  
 1. Funding Source:  Indicate all of the funding source(s) for this study. Check all boxes that apply. 
Provide information regarding the external funding source.  This information should include identification of the agency/sponsor, the funding mechanism (grant or contract), and whether the award is pending or has been awarded. Provide the M/C# and Agency name (if grant-funded).  If the funding source associated with a protocol is ‚Äúpending‚Äù at the time of the protocol submission to the HIC (as is the case for most NIH submissions), the PI should note ‚ÄúPending‚Äù in the appropriate section of the protocol application, provide the M/C# and Agency name (if grant -funded) and further note that University (departmental) funds support 
the research (until such time that an award is made).    
  
PI  Title of Grant  Name of Funding Source   Funding  Funding Mechanism  
 
Sprenkle   
Internal    Federal  
  State  
  Non Profit  
  Industry 
  Other For 
Profit  
  Other  
 Grant -M#            
Contract#  
Contract Pending 
  Investigator/Department 
Initiated  
  Sponsor Initiated 
  Other, Specify: 
 
 
     Federal  
  State  
  Non Profit  
  Industry 
  Other For 
Profit  
  Other  
 Grant -M#            
Contract#  
Contract Pending 
  Investigator/Department 
Initiated  
  Sponsor Initiated 
  Other, Specify: 
 
Page 6 of 24 
  
     Federal  
  State  
  Non Profi t 
  Industry 
  Other  For 
Profit  
  Other  
 Grant -M#            
Contract#  
Contract Pending 
  Investigator/Department 
Initiated  
  Sponsor Initiated 
  Other, Specify:  
 
 
IRB Review fees are charged for projects funded by Industry or Other For-Profit Sponsors.  
Provide the Name and Address of the Sponsor Representative to whom the invoice should be sent.  Note : the PI‚Äôs home department will be bille d if this information is not provided.  
 Send IRB Review Fee Invoice To:  
 Name:  
 Company: 
Address: 
  2. Research Team:  List all members of the research team. Indicate under the affiliation column whether 
the investigato rs or study personnel are part of the Yale faculty or staff, or part of the faculty or staff 
from a collaborating institution, or are not formally affiliated with any institution. ALL members of 
the research team MUST complete Human Subject Protection Trai ning (HSPT) and Health 
Insurance Portability and Accountability Act (HIPAA) Training  before they may be listed on the 
protocol.  See NOTE below.  
 
NOTE: The HIC will remove from the protocol any personnel who have not completed required training. A personnel protocol amendment will need to be submitted when training  is completed . 
  
 Name  Affiliation: Yale/Other Institution 
(Identify) 
 Net ID  
Principal 
Investigator  Preston C. Sprenkle  Yale  University, Dept of Urology  PS577 
Co-
Investigator(s)  Brian Shuch  Yale University, Dept of Urology  bms53  
 
    
 
    
 
    
 
 Kamyar Ghabili Amirkhiz  Yale University, Dept of Urology  Kga25  
 
 Jamil Syed  Yale Urology  Js3569  
Study 
Personnel  Marta Boeke  Yale University, Dept of Urology  Mb273  
 
 Cayce Nawaf  Yale, Department of Urology  Cbn8  
Page 7 of 24 
 SECTION IV: 
 PRINCIPAL INVESTIGATOR /FACULTY ADVISOR / DEPARTMENT CHAIR 
AGREEMENT  
 
 
          As the principal investigator  of this research project, I certify th at: 
ÔÇß The information provided in this application is complete and accurate. 
ÔÇß I assume full responsibility for the protection of human subjects and the proper conduct of the 
      research.  
ÔÇß Subject safety will be of paramount concern, and every effort will be made to protect subjects‚Äô  
      rights and welfare.  
ÔÇß The research will be performed according to ethical principles and in compliance with all federal,  
      state and local laws, as well as institutional regulations and policies regardin g the protection of   
      human subjects. ÔÇß All members of the research team will be kept apprised of research goals.  
ÔÇß I will obtain approval for this research study and any subsequent revisions prior to my initiating the 
      study or any change and I will obtain continuing approval of this study prior to the expiration date            of any approval period. ÔÇß I will report to the HIC any serious injuries and/or other unanticipated problems involving risk to 
      participants.  
ÔÇß I am in compliance with the r equirements set by the University  and qualify to serve as the 
      principal investigator of this project or have acquired the appropriate approval from the  
      Dean‚Äôs Office or Office of the Provost, or the Human Subject Protection Administrator at       Yale-New Haven Hospital, or have a faculty advisor. ÔÇß I will identify a qualified successor should I cease my role as principal investigator and f acilitate a  
smooth transfer of investigator responsibilities.  
__Preston C. Sprenkle___            
  PI Name (PRINT) and Signature      Date  

Page 8 of 24 
  
                    
Department Chair‚Äôs Assurance Statement  
Do you know of any real or apparent institutional conflict  of interest (e.g., Yale ownership of a 
sponsoring company, patents, licensure) associated with  this research  project?  
 Yes (provide a description of that interest in a separate letter addressed to the HIC.) 
 No 
 
As Chair,  do you have any real or apparent protocol -specific conflict o f interest between yourself and  
the sponsor of the research project, or its competitor or any interest in any intervention and/or method 
tested in  the project  that might compromise this research  project? 
Yes (provide a description of that interest in a separate letter addressed to the HIC) 
No 
 
I assure the HIC that the principal investigator and all members of the  research team are qualified by  
education, trainin g, licensure and/or experience to assume participation in the conduct of this research 
trial. I also assure that the principal investigator has departmental support and sufficient resources to  
conduct this trial appropriately. 
 
   ____________________________        
   Chair  Name (PRINT) and Signature           Date  
 
   _________________________________ 
   Department  
   
Page 9 of 24 
  
YNHH Human Subjects Protection Administrator Assurance Statement  
Required when the study is conducted solely at YNHH by YNHH health care providers.  
 
As Human Subject Protection Administrator (HSPA) for YNHH, I certify that: 
ÔÇß I have read a copy of the protocol and approve it being conducted at YNHH. 
ÔÇß I agree to notify the IRB if I am aware of any real or apparent institutional conflict of inter est. 
ÔÇß The principal investigator of this study is qualified to serve as P.I. and has the support of the hospital 
for this research project.  
 
  ______________________________________         
    YNHH HSPA Name (PRINT) and Signature           Date  
 
 
 
 
For HIC  Use Only  
 
              
Date Approved      Human Investigation Committee Signature 
 
This protocol is valid through ______________________________________________ 
 
 
 
SECTION  V: RESEARCH PLAN 
 
1. Statement of Purpose:  State the scientific aim(s) of the study, o r the hypotheses to be tested.   
Specific Aims: 
1.Determine the incidence of prostate cancer in men with the BRCa2 gene mutation  as an 
independent indicator for prostate cancer screening . 
2. Background:  Describe the background information that led to the plan for this project. 
Provide references to support the expectation of obtaining useful scientific data.  
 
Prostate cancer remains the most commonly diagnosed malignancy among men with an 
estimated 230,000 incident cases annually in the U.S.  Emphasis has been placed on 
overtreatment, but prostate cancer remains the most lethal malignancy for men.  Genetic factors, like a family history of prostate cancer, are associated with a higher risk of developing 
the disease, but a connection with more aggressive disease is controversial.  Recently, the 
BRCA mutation, commonly known for its role in breast and ovarian cancer, has been identified 
as risk factor for prostate cancer in men that may also confer a risk of developing more 
aggressive prostate cancer at a younger a ge. While several retrospective studies of men with 
prostate cancer suggest that BRCA2 mutation carriers are at significantly higher risk of developing prostate cancer at an earlier age and more advanced stage,  [1-4
] prospective data is 
lacking. Concern about whether this mutation confers more advanced disease and worse 
survival may contribute to significant anxiety in some men.  A man in England with a BRCA2 
mutatio n, for example,  was so worried about his possible risk of prostate cancer that he had a 
Page 10 of 24 
 prophylactic surgical removal of his prostate[ 5].  This example clearly illustrates the key 
knowledge gaps that exist about the actual risk  of prostate cancer among BRCA2 mutation 
carriers.  
 
We have established a multidisciplinary group of radiation oncologists, urologists, geneticists 
and engineers that is uniquely positioned to address this knowledge gap about the importance 
of the BRCA mutation and risk of prostate cancer.  Our group has developed the Yale School of 
Medicine Fusion Prostate Biopsy  Program. This program uses cutting -edge multiparametric 
magnetic resonance imaging (MRI) to identify previously invisible lesions in the prostate. The office -based Artemis platform (Eigen, Grass Valley CA)  then ‚Äúfuses‚Äù these images with 3D 
ultrasound to achieve more precise and accurate prostate biopsies , allowing for better clinical 
staging with a single biopsy.  The Yale Fusion Prostate Biopsy Program has dramatically improved prostate cancer detection to  more than 60%, almost twice that of the current standard 
of care.   Through t he Yale Cancer Center Genetic Counseling program , which  provides genetic 
counseling and testing to people at increased risk for hereditary cancer, we have an established 
cohort of  families with known genetic mutations including BRCA2.  
 
Our study, by combining the Fusion Prostate Biopsy Program and the Genetic Counseling program to perform highly sensitive prostate biopsies in a population of BRCA2 mutation 
carriers, is a novel approach to accurately determine the risk of prostate cancer, adverse pathologic features and abnormal MRI findings among BRCA2 mutation carriers. While it is 
beyond the scope of this pilot grant, we believe that early identification of men with higher risk 
disease should allow for more rapid treatment and a higher likelihood of cure.  We hypothesize 
that the BRCA -2 mutation is associated with a higher risk of prostate cancer incidence, worse 
grade, and abnormal MRI findings compared to patients without this mutation.  To address these important questions, our specific aims are:  
 
1. To prospectively determine the incidence of prostate cancer in BRCA2 mutation carriers.    
2. To investigate different characteristics of MRI -detected prostate lesions.    
   
3. To compare pathologic  and clinical  findings to clinically matched controls  using the same 
sensitive MRI -based biopsy technique . 
4.  
Localized prostate cancer is treatable and often curable while metastatic disease is not,  hence 
prostate cancer screening is performed to identify  patients at an earlier stage . Early d etection  
of prostate cancer in this group of younger men at high-risk population may  allow for 
identification while at a lower stage and grade, potentially increasing the number of patients 
able to receive treatment with curative intent.  
 All previous studies in the literature have evaluated the incidence of BRCA2 mutation 
carriers in a population of patients already diagnosed with prostate cancer.  The incidence of prostate cancer in men with a BRCA2 mutation, however, has not been previously described. 
 
3. Research Plan:  Summarize the study design and research procedures using non- technical 
language that can be readily understood by someone outside the discipline. Be sure to 
distinguish between standard of care vs. research procedures when applicable, and include 
any flowcharts of visits specifying their individual times and lengths.  Describe the setting in 
which the research will take place.  
Page 11 of 24 
  
This is a cohort screening study to prospectively identify the incidence of prostate cancer in a 
population of BRCA2 carriers .  All men identified to have a BRCA2 mutation as part of the 
Yale Cancer Genetic Counseling Program will be approached and offered participation in the 
study via our program newsletter, BRCA listserv, F acebook page and a targeted mailing.  We 
will also contact all female BRCA2 carriers and ask them to invite their male relatives known 
to carry BRCA2 mutations into this study through the same means.  For patients who test positive for a BRCA2 mutation after this study has opened, we will discuss this study with them at result disclosure and include it as part of their summary letter.  
Potential participants will meet with a urologic oncologist to discuss the risks and benefits of prostate cancer screening i ncluding individual risks and benefits of PSA testing, prostate 
examination, pelvic MRI, 
prostate biopsy, and a prostate cancer diagnosis ..   
Standard of care screening at the Yale Cancer Center for men with a normal prostate cancer 
risk consists of a PSA test and prostate physical examination  beginning at age 50 years and if 
either is abnormal an MRI of the prostate followed by Fusion-targeted biopsy of the prostate is performed  (Figures 1 and 2).  Men with genetic risk factors such as African American or 
Caribbean heritage,  a positive family history of prostate cancer, or a BRCA2 mutation, are 
counseled about their increased risk of prostate cancer and that prostate cancer screening (PSA and prostate exam then MRI and prostate biopsy if indicated) should b egin at age 40yr 
but is available to them at any age.  
Study participants will be identified because of their BRCA2 mutation that places th em at 
increased  risk for developing prostate cancer.  
Because this is a pre -selected high -risk 
population,  and our goal is to establish the incidence of cancer and association of risk factors 
with developing disease,  all men ‚â•30 years of age, able to give informed consent, and with 
at least a 5- 10 year life expectancy  will have PSA testing, prostate examination, Pelvic MRI, 
and Artemis fusion prostate biopsy (Figures 1 and 2).   
Men identified to have prostate cancer will be treated according to current standards of care. 
Treatment for prostate cancer at the Yale Cancer Center is largely based on clinical risk; options include, but are not limited to, active surveillance for appropriate men with low risk 
disease, treatment with curative intent for men with localized intermediate and high risk 
prostate cancer, and systemic therapy for men with metastatic disease. 
  
 
Figure 1. Instrument set up at Yale to perform precision 
imaging -guided biopsy. The prototype device of Artem is 
3D biopsy tracking system. Instrument set up at Yale from 
Eigen (510K approved).  
 
Figure 2. Precision image -guided biopsy. A+B) Identification of 
suspicious regions in two MRI sequences C) overla y of MR contoured 
region on realtime US view D+E) two planes of view of the 3D model 
generated by US and MR segmentation F) matching whole mount 
histology  slide following prostatectomy.  
Page 12 of 24 
 Typical  clinical workflow for an Artemis MR -US fusion biopsy includes a pre- procedure 
MRI followed by a 12- core transrectal -ultrasound (TRUS) guided biopsy (Figure 1,2). The 
ultrasound transducer is fixed with a needle guide, and the biopsy needle is then guided to 
specific regions in the prostate gland for systematic sampling of the gland. If any areas 
suspicious for cancer (labeled regions of interest (ROIs)) are identified in the MRI, they are 
outlined using specialized software, and the target is visible on the Artemis device. Targeted 
biopsies will be taken from each ROI  to rule out cancer in these suspicious areas. 
 
 
3DJHRI
0HQZLWK%5&$PXWDWLRQ 
¬ï\HDUVROG¬ï\UOLIHH[SHFWDQF\ 

3DUWLFLSDWHLQ6WXG\
36$'5(3URVWDWH05,
)XVLRQ3URVWDWH%LRSV\'RQRWSDUWLFLSDWHLQ6WXG\
2IIHUHG36$DQG'5(&RXQVHOHGDERXWSURVWDWHFDQFHU
VFUHHQLQJDQGULVNVEHQHILWVRIWHVWLQJ
DQGFDQFHUGHWHFWLRQ
36$RU'5(
DEQRUPDO
5HFRPPHQG
3URVWDWH05,
DQG)XVLRQ
3URVWDWH%LRSV\
'HWHFW3URVWDWH
&DQFHU([SHULPHQWDO$UP 6WDQGDUGRI&DUH$UP
36$DQG'5(
QRUPDO
5HFRPPHQG
UHSHDW36$DQG
'5(LQRQH\HDU
1R3URVWDWH
&DQFHU
'LVFXVVWUHDWPHQW
RSWLRQV
Page 14 of 24 
  
 
4. Genetic Testing    N/A  
 
5. Subject Population: Provide a detailed description of the types of human subjects who will 
be recruited into this study. 
 
Men ‚â•30 years of age with known BRCA2 mutation and able to give informed consent.   
 
6.  Subject classification: Check off all classifications of subjects that will be specifically 
recruited  for enrollment  in the research project.  Will subjects who may require additional 
safeguards or other considerations be enrolled in the study? If so, identify the population of 
subjects requiring special safeguards and provide a justification for their involvement. 
 
 Children    Healthy   Fetal material, placenta, or dead fetus  
 Non -English Speaking  Prisoners    Economically disadvantaged persons 
 Decisionally Impaired   Employees    Pregnant women and/or fetuses 
 Yale Students   Females of childbearing potential 
 
NOTE: Is this research proposal designed to enroll children who are wards of the state as potential subjects? 
 Yes   No (If yes, see Instructions section VII #4 for further 
requirements)  
  
7. Inclusion/Exclusion Criteria : What are the criteria used to determine subject inclusion or    
exclusion?  
All men ‚â•30 years of a ge with at least a ten -year life expectancy , a known BRCA2 mutation, 
ability to have an MRI, and able to give informed consent will be approached to participate in the study.  If a man has received or is currently receiving treatment for prostate cancer he 
will be excluded from the study. 
 
 
8. How will eligibility  be determined, and by whom?  
Yale genetic counselors  will determine  initial eligibility from the BRCA2 registry  to confirm 
the presence of a BRCA2 mutation.  Trained physicians will determine clinical eligibility based on medical history.  
9. Risks:  Describe the reasonably foreseeable risks, including risks to subject privacy, 
discomforts, or inconveniences associated with subjects participating in the research.  
Risks of prostate biopsy include: infecti on, rectal bleeding, blood in urine or semen, 
prostatitis,  urosepsis, urinary retention, and potential difficulty with urination.  
Magnetic resonance (MR) is a technique that uses magnetism and radio waves, not x -
rays, to take pictures and measure chemical s of various parts of the body.  The United States 
Food and Drug Administration (FDA) has set guidelines for magnet strength and exposure to radio waves, and we carefully observe those guidelines.   

Page 15 of 24 
 Patients will be watched closely throughout the MR study.  Some people may feel 
uncomfortable or anxious.  If this happens to you, you may ask to stop the study at any time 
and we will take you out of the MR scanner.  On rare occasions, some people might feel dizzy, get an upset stomach, have a metallic taste or  feel tingling sensations or muscle 
twitches.  These sensations usually go away quickly but please tell the research staff if you have them.   
There are some risks with an MR study for certain people.  If someone has  a pacemaker 
or some metal objects insid e their body, they may not be in this study because the strong 
magnets i n the MR scanner might harm them.  Another risk is a metallic object flying 
through the air toward the magnet and hitting the participant .  To reduce this risk we require 
that all people involved with the study remove all metal from their clothing and all metal objects from their pockets.  Nothing metal can be brought into the magnet room at any time.  Also, once the participant is  in the magnet, the door to the room will be closed so that no one 
from outside accidentally goes near the magnet.  
 
 
 
 
10. Minimizing Risks:  Describe the manner in which the above- mentioned risks will be 
minimized.  
Risks will be minimized using standard of care methods to limit prostate biopsy- related 
patient disco mfort and the risk of infection through administration of local anesthetic and 
peri-procedure antibiotics, respectively. 
FDA guidelines for MRI safety are strictly adhered to.  
 
11. Data and Safety Monitoring Plan:  Include an appropriate Data and Safety Monitor ing Plan 
(DSMP) based on the investigator‚Äôs risk assessment stated below. (Note: the HIC will make the final determination of the risk to subjects.) For more information, see the Instructions, page 24. a. What is the investigator‚Äôs assessment of the overall risk level for subjects participating in 
this study?  
 - Moderate risk: participants  will be offered the standard of care fusion targeted 
prostate biopsy that is performed at Yale and offered to other patients at risk for 
prostate cancer .  Some participa nts, however, would not have received a biopsy if not 
participating in the study.  
 1. Personnel responsible for the safety review and its frequency:  
 
The principal investigator will be responsible for monitoring the data, assuring protocol compliance, and conducting the safety reviews at the specified frequency which must be conducted at a minimum of every 6 months (including when reapproval of the protocol is sought).  During the review process, the principal investigator (monitor) will evaluate whether th e study should continue unchanged, require modification/amendment, or close 
to enrollment. Either the principal investigator, the IRB or the Yale Cancer Center Data and Safety Monitoring Committee (DSMC)  have the authority to stop or suspend the 
study or require modifications. 
 
Page 16 of 24 
 2. The risks associated with the current study are deemed moderate for the following 
reasons: (choose those that apply)  
 
1. We do not view the risks associated with the prostate biopsy as minimal given the 
alternative is no biopsy. 
2. Give n the now established safety and validity of the current biopsy procedure in our 
prior work, we do not view the proposed studies as high risk. 
 
Although we have assessed the proposed study as one of moderate risk, the potential exists for anticipated and/o r unanticipated adverse events, serious or otherwise, to occur 
since it is not possible to predict with certainty the absolute risk in any given individual or in advance of first-hand experience with the proposed study methods. Therefore, we provide a plan for monitoring the data and safety of the proposed study as follows: 
      3. Attribution of Adverse Events: 
Adverse events will be monitored for each subject participating in the study and attributed to   the study procedures / design by the principal investigator Preston Sprenkle 
according to the following categories: 
 
a.) Definite: Adverse event is clearly related to investigational procedures(s)/agent(s).  
b.) Probable: Adverse event is likely related to investigational procedures(s)/agent(s). c.) Possible: Adverse event may be related to investigational procedures(s)/agent(s). d.) Unlikely: Adverse event is likely not to be related to the investigational procedures(s)/agent(s). e.) Unrelated: Adverse event is clearly not related to investigational proce dures(s)/agent(s).  
      4. Plan for Grading Adverse Events: 
 
The following scale will be used in grading the severity of adverse events noted during 
the study: 
 
1. Mild adverse event  
2. Moderate adverse event  
3. Severe  
      5. Plan for Determining Seriousness of  Adverse Events:  
      Serious Adverse Events:  
In addition to grading the adverse event, the PI will determine whether the adverse event meets the criteria for a Serious Adverse Event (SAE).  An adverse event is considered serious if it: 
 
1. is life -threateni ng OR  
2. results in in -patient hospitalization or prolongation of existing hospitalization OR  
3. results in persistent or significant disability or incapacity OR  
Page 17 of 24 
 4. results in death OR 
5. based upon appropriate medical judgment, may jeopardize the subject‚Äôs health and 
may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, OR  
6. adversely affects the risk/benefit ratio of the study  
An adverse event may be graded as severe but still not meet the criteria for a Serious Adverse Event.  Similarly, an adverse event may be graded as moderate but still meet the criteria for an SAE.  It is important for t he PI to consider the grade of the event as well as its 
‚Äúseriousness‚Äù when determining whether reporting to the IRB is necessa ry. 
 
6. Plan for reporting Reportable Adverse Events and other unanticipated problems involving risks to subjects or others to the IRB 
 
The principal investigator will report the following types of events to the IRB: a) adverse 
events that are serious or l ife-threatening AND unanticipated (or anticipated but occurring 
with a greater frequency than expected ) AND possibly, probably or definitely related to the 
drug/device/intervention; and b) other unanticipated problems involving risks to subjects or others. 
 
These adverse events or unanticipated problems involving risks to subjects or others will be reported to the IRB in accordance with IRB Policy 710, using the appropriate forms found on the website.  
 
 
7. Plan for reporting adverse events to co -investigators on the study, as appropriate the 
protocol‚Äôs research monitor(s), e.g Yale Cancer Center Data and Safety Monitoring 
Committee (DSMC),  Protocol Review Committee (PRC), DSMBs, study sponsors, funding 
and regulatory agencies, and regulatory and decision- mak ing bodies.  
 
For the current study, the following individuals, funding, and/or regulatory agencies will be 
notified (choose those that apply): 
 
X All Co -Investigators listed on the protocol. 
 
X Yale Cancer Center Data and Safety Monitoring Committee (DSMC)  
‚ñ° National Institutes of Health  
‚ñ° Food and Drug Administration (Physician-Sponsored IND #_______) 
‚ñ° Medical Research Foundation (Grant______) 
 
The principal investigator Preston Sprenkle will conduct a review of all adverse events upon completion of every study subject. The principal investigator will evaluate the frequency and 
Page 18 of 24 
 severity of the adverse events and determine if modifications to the protocol or consent form 
are required.  
 
d. For multi- site studies for which the Yale PI serves as the lead inves tigator: N/A  
 
12. Statistical Considerations:  Describe the statistical analyses that support the study design.  
This is a screening study to establish  the incidence of prostate cancer in a high-risk 
population since it is not currently known.  There is  an estimated  4.6-23 fold increased risk of 
prostate cancer, especially in men < 58 years of age with a BRCA2 mutation. Typically , 
prostate cancer detecti on in normal risk men correlates  directly with age and ranges between 
0.01 and 6.5% for men in their 30s -60s ( CDC website).  Given these parameters, we plan 
initial evaluation of 100 men. 
   
SECTION  VI: RESEARCH INVOLVING DRUGS , BIOLOGICS , RADIOTRACERS , PLACEBOS  AND 
DEVICES  
 
N/A  
 
SECTION  VII: RECRUITMENT /CONSENT AND ASSENT P ROCEDURES   
1. Targeted Enrollment: Give the number of subjects:  
a.   targeted for enrollment at Yale for this protocol__ 100 
b.    If this is a multi- site study, give the total number of subjects targeted across all 
sites___  
 
2. Indicate recruitment methods below.   Attach copies of any recruitment materi als that will 
be used. 
 
 Flyers       Internet/Web Postings    Radio  
 Posters       Mass E -mail Solicitation     Telephone 
 Letter        Departmental/Center Website    Television  
 Medical Record Review     Departmental/Center Research Boards   Newspaper  
 Departmental/Center Newsletters   Web -Based Clinical Trial Registries   
  YCCI Recruitment database    Clinicaltrials.gov Registry (do not send materials to HIC)  
 Other (describe):  
 
3.  Recruitment Procedures:   
a. Describe how potential su bjects will be identified . 
i. Potential subjects will be identified through the Yale Cancer Genetic 
Counseling Program.  
ii. For patients who test positive for a BRCA2 mutation after this study has opened, we will discuss this study with them at result disclosure and include it 
as part of their summary letter
 
b. Describe how potential subjects are contacted.  
Page 19 of 24 
 i. Potential subjects with a known BRCA2 mutation will be approached and 
offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing.  We will also contact all female BRCA2 carriers and ask them to invite their male relatives known to carry BRCA2 mutations into this study through the same means.  
 
ii. For patients who test positive for a BRCA2 mutation after this stu dy has 
opened, we will discuss this study with them at result disclosure and include it as part of their summary letter
 
c. Who is recruit ing potential subjects?  
i. Trained genetic counselors will be recruiting possible subjects.  
  
4. Screening Procedures  
a. Will email or telephone correspondence  be used to screen potential subjects for eligibility 
prior to the potential subject coming to the research office?  Yes   No 
b.  If yes, identify below all health information to be collected  as part of screening and 
check off any of the following HIPAA identifiers to be collected and retained by the research team during this screening process. 
 
 
HEALTH INFORMATION  TO BE COLLECTED : 
 
 
HIPAA identifiers:  
 Names  
 All geographic subdivisions smaller than a State, including: street address, city, county, precinct, zip codes and their 
equivalent geocodes, except for the initial three digits of a zip code if, according to the current publicly -available data from 
the Bureau of the Census: (1) the geographic unit formed by combining all zip codes with the same three initial digits 
contains more than 20,000 people, and (2) the initial three digits of a zip code for all such geographic units containing 
20,000 or fewer people is changed to 000.  
  Telephone numbers  
 Fax numbers  
 E-mail addresses  
 Social Security numbers  
 Medical record numbers  
 Health plan beneficiary numbers  
 Account numbers  
  All elements of dates (except year) for dates related to an individual, including: birth date, admission date, discharge 
date, date of death, all ages over 89 and all elements of dates (including year) indicative of such age, except that such ages and elements may be aggregated into a single category of age 90 or older  
 Certificate/license numbers  
 Vehicle identifiers and serial numbers, including license plate numbers  
 Device identifiers and serial numbers  
 Web Universal Resource Locators (URLs)  
 Internet Protocol (IP) address numbers  
 Biometric identifiers , including finger and voice prints  
 Full face photographic images and any comparable images  
 Any other unique identifying numbers, characteristics, or codes  
 
 
5. Assessment of Current Health Provider Relationship for HIPA A Consideration:  
Does the Investigator or any member of the research team have a direct existing clinical relationship with any potential subject?  

Page 20 of 24 
  Yes, all subjects  
 Yes, some of the subjects 
 No 
 
If yes , describe the nature of this relationship. 
Dr. Sprenkle could potentially see some of these patients while they are undergoing their standard of care prostate cancer treatment.  
  
 
6. Request for waiver of HIPAA authorization:   (When requesting a waiver of HIPAA 
Authorization for either the entire study, or for recruitment purposes only.  Note: if you are collecting 
PHI as par t of a phone or email screen, you must request a HIPAA waiver for recruitment purposes.) 
 
Choose one: For entire study: ______ For recruitment purposes only: ______ 
i. Describe why it would be impracticable to obtain the subject‚Äôs authorization for use/disclo sure of this data; 
ii. If requesting a waiver of signed  authorization, describe why it would be 
impracticable to obtain the subject‚Äôs signed authorization for use/disclosure of this data;  
 By signing this protocol application, the investigator assures that the protected health information for which a Waiver of Authorization has been requested will not be reused or disclosed to any person or entity other than those listed in this application, except as required by law, for authorized oversight of this research study, or as specifically approved for use in another study by an IRB.  
 
Researchers are reminded that unauthorized disclosures of PHI to individuals outside of the Yale HIPAA- Covered entity must be accounted for in the ‚Äúaccounting for disclosures log‚Äù, by s ubject 
name, purpose, date, recipients, and a description of information provided.  Logs are to be forwarded to the Deputy HIPAA Privacy Officer.  7. Required HIPAA Authorization:  If the research involves the creation, use or disclosure of 
protected health information (PHI), separate subject authorization is required under the HIPAA Privacy Rule. Indicate which of the following forms are being provided: 
    Compound Consent and Authorization form 
    HIPAA Research Authorizati on Form 
  8. Consent Personnel:  List the names of all members of the research team who will be obtaining 
consent/assent.  Preston Sprenkle 
 
 
 

Page 21 of 24 
 9. Process of Consent/Assent:  Describe the setting and conditions under which consent/assent will 
be obtained, including parental permission or surrogate permission and the steps taken to ensure 
subjects‚Äô independent decision-making.  
Prior to screening for prostate cancer  patients will have an office visit as part of standard clinical 
care to discuss the risks and benefits of prostate cancer screening.  During this visit, if they are 
interested in being screened for prostate cancer  and meet eligibility criteria  the study will be 
described and if patients are interested in participating they will be provided a study information 
sheet and asked  to sign consent. Only patients that can provide written informed consent will be 
enrolled in this study, and if there is any doubt subjects will not be enrolled. Information sheets will also be available to patients  as part of the Yale Cancer Genetic Counseling Program.  
  
10. Evaluation of Subject(s) Capacity to Provide Informed Consent/Assent:  Indicate how the 
personnel obtaining consent will assess the potential subject‚Äôs ability and capacity to consent to the research being proposed.  
 Preston Sprenkle, after explaining the research plan orally, and after providing time for subjects 
to review written information from an informational flyer, will ask open -ended questions to 
gauge subject comprehension and capacity to provide informed consent . Questions will include: 
‚ÄúCan you tell me what happens if you agree to take part in this study?‚Äù and ‚ÄúWhat should you do if you no longer want to take part in the study?‚Äù    
11. Documentation of Consent/Assent:  Specify the documents that will be used during t he 
consent/assent process. Copies of all documents should be appended to the protocol, in the same format that they will be given to subjects.  
 An adult consent form will be provided, and is attached.    
12. Non-English Speaking Subjects:  Explain provisions in place to ensure comprehension for 
research involving non-English speaking subjects. Translated copies of all consent materials must be submitted for approval prior to use.  
 
13. Consent  Waiver: In certain circumstances, the HIC may grant a waiver of signed consent, or 
a full waiver of consent, depending on the study. If you will request either a waiver of consent, 
or a waiver of signed consent for this study, complete the appropriate section below.   
  Not Requesting a consent waiver  
  Requesting a waiver of signed consent  
        Requesting a full waiver of consent  
    
 
A. Waiver of signed  consent : (Verbal consent from subjects will be obtained. If PHI is 
collected, information in this section must match Section VI I, Question 6) 
 Requesting a waiver of signed consent for Recruitment /Screening  only  
Page 22 of 24 
 If requesting a waiver of signed consent, please address the following: 
a. Would the signed consent form be the only record linking the subject and the research? 
 Yes   No 
b. Does a breach of confidentiality constitute the principal risk to subjects?  
 Yes   No 
 
    OR 
 
c. Does the research  activity pose greater than minimal risk?  
 Yes If you answered yes, stop. A waiver cannot be granted.  Please note: 
Recruitment/screening is generally  a minimal risk research activity   
 No  
AND 
d. Does the research include any activities that would require signed consent in a non-
research context?  Yes   No 
 
 Requesting a waiver of signed consent for the Entire Study  (Note that an information 
sheet may be required.)  
   If requesting a waiver of signed consent, ple ase address the following:  
a. Would the signed consent form be the only record linking the subject and the research? 
 Yes   No 
b. Does a breach of confidentiality constitute the principal risk to subjects?  
 Yes   No 
 
    OR 
 
c. Does the research pose greater than minimal risk?  Yes If you answered yes, stop. A 
waiver cannot be granted.     No  
AND 
d. Does the research include any activities that would require signed consent in a non-research context? 
 Yes   No 
   
 B. Full waiver  of consent: (No consent from subjects will be obtained for the activity .)  
 Requesting a waiver of consent for Recruitment/ Screeni ng only  
a. Does the research activity pose greater than minimal risk to subjects?   
 Yes  If you answered yes, stop. A waiver cannot be granted. Please note: 
Recruitment/screening is generally  a minimal risk research activity  
 No 
   b. Will the waiver adversely affect subjects‚Äô rights and welfare?  Yes   No 
   c. Why would the research be impracticable to conduct without the waiver?  
 d. Where appropriate, how will pertinent information be returned to, or shared with 
subjects at a later date?  
 
 
 Requesting a full waiver of consent for the Entire S tudy  (Note: If PHI is 
collected, information here must match Section VII, question 6.) 
Page 23 of 24 
     
If requesting a full waiver of consent, please address the following: 
 
   a. Does the research pose greater than minimal risk to subjects?   
 Yes  If you answered yes, stop. A waiver cannot be granted.   
 No 
   b. Will the waiver adversely affect subjects‚Äô rights and welfare?  Yes   No 
   c. Why would the research be impracticable to conduct without the waiver?  
 d. Where appropriate, how will pertinent information be returned to, or shared with 
subjects at a later date?  
 
SECTION  VIII: PROTECTION OF RESEARCH SUBJECTS  
 
    Confidentiality & Security of Data:  
a. What protected health information (medical information along with the HIPAA 
identifiers)  about subjects will be collected and used for the research?   
b. Subject Name, date o f birth, and Medical Record number as well as clinical imaging, 
pathologic and staging information will be collected.     
        
c. How will the research data be collected, recorded and stored?  
All research data will be collected  as part of the medical reco rd and stored in a secure ITS 
managed database (FMS Med). Only co -investigators will be able to collect, record and access 
this workstation, and no collaborators on this study will have access to PHI. 
d.  
c.    How will the digital data be stored?  CD   DVD   Flash Drive   Portable Hard    
       Drive   Secured Server   Laptop Computer   Desktop Computer   Other  
d.    What me thods and procedures will be used to safeguard the confidentiality and security of     
the identifiable study data and the storage media indicated above during and after the 
subject‚Äôs  participation in the study?  
The data will be stored on and ITS managed secure database in the medical school, 
accessible only by co -investigators  
Do all portable devices contain encryption software?  Yes    No 
         If no, see http://hipaa.yale.edu/guidance/policy.html  
  
e. What will be done with the data when the research is completed? Are there plans to 
destroy      the identifiable data? If yes, describe how, by whom and when identifiers will 
be destroyed.  If no, describe how the data and/or identifiers will be secured.  
All identifies will be secured in an encrypted database.  
f. Who will have access to the protected health information  (such as the research sponsor, 
the  investigator, the research staff, all research monitors, FDA, Yale Cancer Center 
Data and Safety Monitoring Committee (DSMC) , SSC, etc.)?  (please distinguish 
betw een PHI and de- identified data)  . 
PHI will be accessible by co -investigators only, collaborators will not have access 
g.   If appropriate, has a Certificate of Confidentiality  been obtained? N/A 
h.   Are any of the study procedures likely to yield information subject to mandatory reporting   requirements? (e.g. HIV testing ‚Äì reporting of communic able diseases; parent interview -

Page 24 of 24 
 incidents of child abuse, elderly abuse, etc.). Please verify to whom such instances will need to 
be reported.  N/A  
 
SECTION  IX: POTENTIAL BENEFITS  
 
 Potential Benefits:  Identify any benefits that may be reasonably expected  to result from the 
research, either to the subject(s) or to society at large. (Payment of subjects is not considered a benefit in this context of the risk benefit assessment.)  
 Prostate cancer could potentially be discovered at an earlier and more localized stage allowing for greater chance of cure with treatment.  
  
         S ECTION  X: RESEARCH ALTERNATIVES AND ECONOMIC CONSIDERATIONS  
 1.     Alternatives:  What other alternatives are available to the study subjects outside of the research?  
There is no cur rent alternative .  Patients may request to be screened for prostate cancer with 
standard of care management  
2.  Payments for Participation (Economic Considerations):  Describe any payments that will be 
made to subjects , the amount and schedule of payments, and the conditions for receiving this 
compensation.  ‚Äì no payment for participation 
 3. Costs for Participation (Economic Considerations):  Clearly describe the subject‚Äôs costs 
associated with participation in the research, and the interventions or procedures of the study that 
will be provided at no cost to subjects.   - No cost to participate, all research will be performed 
as part of standard prostate cancer screening.   
 
4. In Case of Injury:   
 If a patient is injured while on study, he should seek treatment and contact the study doctor as soon a s he is able. Yale School of Medicine and Yale-New Haven Hospital do not provide funds 
for the treatment of research -related injury. If the patient is injured as a result of participation in 
this study, treatment will be provided. He or his insurance carri er will be expected to pay the 
costs of this treatment. No additional financial compensation for injury or lost wages is available.  